“从不吸烟的患者对一类叫表皮生长因子受体抑制剂的药物反应更好，因为这类患者有表皮生长因子受体基因突变的可能性更大一些。”鲁丁说。
"Patients who never smoked respond better to a certain class of drugs called EGFR inhibitors, because lung cancer in these patients more often contain mutations in the EGFR gene," Rudin says.
采用分子动力学和MM/PBSA相结合的方法预测了表皮生长因子受体和4-苯胺喹 啉类抑制剂的相互作用模式。
The possible binding mode between EGFR and a 4-anilinoqunazoline inhibitor was predicted by using molecular dynamics and MM/PBSA.
采用分子动力学和MM/PBSA相结合的方法预测了表皮生长因子受体和4-苯胺喹 啉类抑制剂的相互作用模式。
The possible binding mode between EGFR and a 4-anilinoqunazoline inhibitor was predicted by using molecular dynamics and MM/PBSA.
应用推荐